直肠癌组织中SMYD3的表达及临床意义

Expression and clinical significance of SMYD3 in rectal cancer

目的研究直肠癌组织中组蛋白甲基化转移酶3(SMYD3)的表达水平及临床意义。方法采用免疫组织化学方法和免疫蛋白印迹法(Western blot)分别检测64例直肠癌组织及对应的癌旁组织中SMYD3的表达。分析SMYD3表达与直肠癌临床病理特征及预后的关系。结果直肠癌组织中SMYD3的表达率为60.94%,高于癌旁组织的表达率14.06%,差异有统计学意义(χ^2=30.00、P<0.05)。直肠癌组织中SMYD3的表达与患者年龄、性别、组织分化程度无关(均P>0.05),与TNM分期、浸润深度及淋巴结转移相关(均P<0.05)。SMYD3阳性表达者的预后较阴性表达者差(P<0.05)。SMYD3蛋白在直肠癌组织中表达量(1.26±0.31)明显高于对应的癌旁组织(0.55±0.22)(t=11.95、P<0.05)。结论SMYD3的表达升高与直肠癌的发生发展有关,其表达水平可作为直肠癌恶性程度判定及预后评估的指标。本研究结果表明,SMYD3参与直肠癌的发生发展,本研究结果可为SMYD3作为直肠癌靶向治疗的新靶点及预后预测因子提供基础。

Objective To study the expression level and clinical significance of SET and MYND domain-containingprotein 3(SMYD3)in rectal cancer tissues.Methods Immunohistochemistry and Western blot were used to detect the expression of SMYD3 in 64 cases of rectal cancer tissues and corresponding adjacent tissues.The relationship between SMYD3 expression and clinicopathological characteristics and prognosis of rectal cancer were analyzed.Results The expression rate of SMYD3 in rectal cancer tissue was 60.94%,which was higher than that in adjacent tissues by 14.06%,and the difference was statistically significant(χ^2=30.00,P<0.05).The expression of SMYD3 in rectal cancer tissue has no correlation with the patient's age,gender,and degree of tissue differentiation(all P>0.05),but has correlation with TNM staging,depth of invasion and lymph node metastasis(all P<0.05).The prognosis of the rectal cancer patients with positive expression of SMYD3 was worse than that with negative expression(P<0.05).The expression of SMYD3 protein in rectal cancer tissues(1.26±0.31)was significantly higher than that in the corresponding adjacent tissues(0.55±0.22)(t=11.95,P<0.05).Conclusions The increased expression of SMYD3 is related to the occurrence and development of rectal cancer,and its expression level can be used as an index for judging the malignancy of rectal cancer and evaluating its prognosis.The results of this study show that SMYD3 is involved in the occurrence and development of rectal cancer.The results of this study can provide a basis for SMYD3 as a new target for rectal cancer targeted therapy and a prognostic criterion.